Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 12/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 5/20 | 1.00 |
| ▸ | RET | P07949 | 5/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 4/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 3/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 3/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 1.00 |
| ▸ | STK10 | O94804 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | BCR | P11274 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | DDR1 | Q08345 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenvatinib SCHEMBL29372021 | 1.00 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29349806 | 1.00 | FGFR4 (1.00) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL1389214 | 0.99 | FGFR4 (0.98) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL865174 | 0.97 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29357626 | 0.97 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL29368684 | 0.97 | FGFR4 (0.94) | FGFR4KDRFGFR1PDGFRARET | |
| Lenvatinib SCHEMBL3928020 | 0.95 | FGFR4 (0.91) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL28586143 | 0.95 | FGFR4 (0.91) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL1248140 | 0.93 | FGFR4 (0.87) | FGFR4KDRFGFR1PDGFRARET | |
| SCHEMBL30083661 | 0.92 | FGFR4 (0.86) | FGFR4KDRFGFR1PDGFRARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1049 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667005-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | Eisai R&D Management Co., Ltd. (JP) | 2025-12-24 | — | — | EP | claimed |
| EP-3737377-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MAN CO LTD (JP) | 2025-10-08 | — | — | EP | claimed |
| US-12102630-B2 | Crystalline forms and processes of lenvatinib besylate | SYNTHON B.V. (NL) | 2024-10-01 | — | — | US | claimed |
| EP-3384901-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB MESYLATE | SYNTHON BV (NL) | 2024-08-14 | — | — | EP | claimed |
| US-12059429-B2 | Hornerin: a novel non-VEGF mediated angiogenic protein expressed in both human and mouse angiogenic endothelial cells and human pancreatic cancer cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-08-13 | — | — | US | claimed |
| EP-3860605-B9 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB BESYLATE | SYNTHON BV (NL) | 2024-07-03 | — | — | EP | claimed |
| US-11911509-B2 | Pharmaceutical composition comprising Lenvatinib mesylate | SYNTHON B.V. (NL) | 2024-02-27 | — | — | US | claimed |
| CN-111689897-B | Preparation method of high-purity lenvatinib mesylate crystal form C | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-11833119-B2 | Combination therapies for the treatment of hepatocellular carcinoma | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-05 | — | — | US | claimed |
| EP-3860605-B1 | PHARMACEUTICAL COMPOSITION COMPRISING LENVATINIB BESYLATE | SYNTHON BV (NL) | 2023-11-08 | — | — | EP | claimed |
| US-20070117842-A1 | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-24 | — | — | US | claimed |
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-04-05 | — | — | US | claimed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | claimed |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| EP-1698623-A1 | CRYSTAL OF SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINO-PHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR OF SOLVATE THEREOF AND PROCESSES FOR PRODUCING THESE | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| EP-1604665-A1 | C-KIT KINASE INHIBITOR | Eisai Co., Ltd. (JP) | 2005-12-14 | — | — | EP | claimed |
| US-20040253205-A1 | c-Kit kinase inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | claimed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911509-B2 | Pharmaceutical composition comprising Lenvatinib mesylate | ETV6, ALK, KRAS | KDR 37/4885FLT1 32/4885FLT4 14/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | KDR 22/4885FLT1 4/4885FLT4 13/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885FLT1 3/4885FLT4 1/4885 |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | CA7, CA4, CHIA | KDR 4339/4885FLT1 4790/4885FLT4 3881/4885 |
| US-20070117842-A1 | Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same | CYP3A4, CYP3A7, CYP2D6 | KDR 2743/4885FLT1 3472/4885FLT4 1796/4885 |
| US-20070078159-A1 | A CRYSTALLINE FORM OF THE SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMIN OPHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR THE SOLVATE OF THE SALT AND A PROCESS FOR PREPARING THE SAME | AQP4, UACA, AQP3 | KDR 3394/4885FLT1 3838/4885FLT4 2668/4885 |
| US-20040253205-A1 | c-Kit kinase inhibitor | KIT, MASTL, TNNI3K | KDR 368/4885FLT1 437/4885FLT4 505/4885 |
| US-12102630-B2 | Crystalline forms and processes of lenvatinib besylate | SQSTM1, MAP1LC3B, ULK1 | KDR 118/4885FLT1 25/4885FLT4 20/4885 |
| US-11833119-B2 | Combination therapies for the treatment of hepatocellular carcinoma | FGFR4, FLT4, FGFR3 | KDR 23/4885FLT1 12/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.